Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026)

Vertex Pharmaceuticals' Tax Provisions history runs 16 years deep, the most recent figure standing at $221.5 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 163.38% year-over-year to $221.5 million; the TTM figure through Mar 2026 stood at $827.4 million (up 20.14% YoY), while the FY2025 annual figure was $690.0 million, down 12.0% from the prior year.
• Tax Provisions was $221.5 million for Q1 2026 at Vertex Pharmaceuticals, up from $139.9 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $257.9 million in Q4 2022 to a low of $84.1 million in Q1 2025.
• Historically, Tax Provisions has averaged $198.0 million across 5 years, with a median of $202.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Tax Provisions surged 292.36% in 2022, then sank 53.15% in 2025.
• A 5-year view of Tax Provisions shows it stood at $257.9 million in 2022, then tumbled by 30.67% to $178.8 million in 2023, then grew by 25.0% to $223.5 million in 2024, then tumbled by 37.4% to $139.9 million in 2025, then soared by 58.33% to $221.5 million in 2026.
• The last three Tax Provisions figures came in at $221.5 million (Q1 2026), $139.9 million (Q4 2025), and $215.9 million (Q3 2025), per Business Quant data.